| Bioactivity | Leritrelvir (RAY1216) is an orally active SARS-CoV-2 main protease slow-tight inhibitor with a Ki of 8.6 nM[1]. |
| Target | Ki: 8.6 nM (SARS-CoV-2 main protease) |
| Invitro | Leritrelvir (RAY1216) 的药物靶向停留时间为 104 分钟[1]。Leritrelvir 通过 α-ketoamide warhead 共价连接到催化的 Cys145 上[1]。Leritrelvir (0-1000 nM; 72 h) 显示出对 SARS-CoV-2 野生型祖先株和变异株的抗病毒活性[1]。 Cell Viability Assay[1] Cell Line: |
| In Vivo | Leritrelvir (RAY1216) (150-600 mg/kg/day; i.g.; 5 days) 有效延长 SARS-CoV-2 感染小鼠的生存[1]。Compound pharmacokinetics parameters in different animal species[1] Compound |
| Name | Leritrelvir |
| Formula | C31H44F3N5O6 |
| Molar Mass | 639.71 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Chen X, et al. Inhibition mechanism and antiviral activity of an α-ketoamide based SARS-CoV-2 main protease inhibitor. bioRxiv, 2023: 2023.03. 09.531862. |